GHP Q1 2018

GHP / Q1 2018 5 NEWS , LyondellBasell is one of the largest plas- tics, chemicals and refining companies in the world. Driven by its 13,000 employees around the globe, LyondellBasell produc- es materials and products that are key to advancing solutions to modern challenges like enhancing food safety through lightweight and flexible packaging, protect- ing the purity of water supplies through stronger and more ver- satile pipes, and improving the safety, comfort and fuel efficiency of many of the cars and trucks on the road. The firm sells products into approximately 100 countries and is the world’s largest licensor of polyolefin technologies. Polyolefin resins used in applica- tions requiring gamma or X-ray irradiation must be correctly ad- ditivated to mitigate the effects of radiation on the polymer structure, which may cause them to turn yellow and become brittle. To ad- dress these requirements and im- prove packaging integrity, the new Purell RP375R has a tailor-made Unique immune detection technology and flexible workflow for tuberculosis control efforts. QIAGEN N.V. has announced that Japan’s Min- istry of Health Labor and Welfare has approved QuantiFER- ON®-TB Gold Plus (QFT®-Plus) as an in vitro diagnostic to detect tuberculosis (TB) infection. QFT-Plus is the fourth gen- eration of QIAGEN’s market-leading QuantiFERON-TB tech- nology, combining innovative CD4+/CD8+ design for com- prehensive immune response detection with the most flexible blood collection workflow for efficient screening in large-scale TB control programs. “QuantiFERON-TB Gold Plus sets a new global standard for latent TB testing. The proprietary CD4+/CD8+ T cell tech- nology of QFT-Plus, with the addition of specific CD8+T cell stimulating antigens, has the potential to provide important insights for high-risk patients such as contacts exposed to active TB or HIV-positive persons,” said Dr. Masae Kawa- mura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN. “In 2015, the Japanese government set a goal to reduce the country’s tuberculosis incidence rate to 10.0 per 100,000 persons by 2020. We are very happy to contribute to achievement of that goal with QFT-Plus becoming an impor- tant tool for use in Japan’s comprehensive TB control efforts.” Japan’s approval of QFT-Plus follows 2017 approval in the United States and successful uptake of the test in more than 75 countries across Europe, the Middle East, Africa, Asia and Latin America, where nearly two million of the new tests have already been used. QFT-Plus builds on the foundation of QuantiFERON-TB Gold® (QFT®), the third generation of QIAGEN’s world-leading interferon gamma release assay (IGRA). additivation package that delivers good impact strength and resist- ance to yellowing. “The good flowability delivered by Purell RP375R will help our cus- tomers produce thin-walled and complex design items in short cycle times and at low conversion temperatures”, said Rodney Fox, marketing manager of Lyondell- Basell’s European PP Healthcare and Caps and Closures business. “Our team is working to innovate and explore new products that help our customers advance qual- ity healthcare.” Purell RP375R is produced with a non-phthalate based catalyt- ic system and offers excellent transparency with good balance of physical and mechanical prop- erties. As part of the Purell family of grades, this resin also benefits from LyondellBasell’s Purell Ser- vice Concept, offering dedicated manufacturing procedures and standards for products to meet customer material requirements for the pharmaceutical and health- care industry. LyondellBasell is bringing tomarket the new Purell RP375R a polypropylene (PP) random copolymer that delivers excellent resistance to gamma and X-ray radiation sterilization. These sterilizationmethods help tominimize risk for patients by reducingmicrobial load on injectionmouldedmedical devices and other healthcare applications. QIAGEN’s QuantiFERON-TB Gold Plus Gains Approval in Japan